Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2015
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin; Ethiodized oil
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Soratace-1
- 15 Mar 2012 Actual end date changed from Nov 2010 to Mar 2011 as reported by European Clinical Trials Database.
- 15 Mar 2012 Actual initiation date changed from Sep 2008 to Mar 2008 as reported by European Clinical Trials Database.
- 08 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.